PMID- 28385383
OWN - NLM
STAT- MEDLINE
DCOM- 20180515
LR  - 20180515
IS  - 1399-0020 (Electronic)
IS  - 0901-5027 (Linking)
VI  - 46
IP  - 8
DP  - 2017 Aug
TI  - Prognostic significance of gene amplification of ACTN4 in stage I and II oral 
      tongue cancer.
PG  - 968-976
LID - S0901-5027(17)31345-0 [pii]
LID - 10.1016/j.ijom.2017.03.001 [doi]
AB  - Despite complete resection of the early stage of oral tongue cancer by partial 
      glossectomy, late cervical lymph node metastasis is frequently observed. Gene 
      amplification of ACTN4 (protein name: actinin-4) is closely associated with the 
      metastatic potential of various cancers. This retrospective study was performed 
      to demonstrate the potential usefulness of ACTN4 gene amplification as a 
      prognostic biomarker in patients with stage I/II oral tongue cancer. Fifty-four 
      patients with stage I/II oral tongue cancer were enrolled retrospectively, in 
      accordance with the reporting recommendations for tumour marker prognostic 
      studies (REMARK) guidelines. The copy number of ACTN4 and the protein expression 
      of actinin-4 were evaluated by fluorescence in situ hybridization (FISH) and 
      immunohistochemistry (IHC), respectively. The overall survival time of patients 
      with gene amplification of ACTN4 was significantly shorter than that of patients 
      without gene amplification (P=0.0010, log-rank test). Gene amplification of ACTN4 
      was a significant independent risk factor for death in patients with stage I/II 
      oral tongue cancer (hazard ratio 6.08, 95% confidence interval 1.66-22.27). Gene 
      amplification of ACTN4 is a potential prognostic biomarker for overall survival 
      in oral tongue cancer.
CI  - Copyright (c) 2017 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Kakuya, T
AU  - Kakuya T
AD  - Division of Chemotherapy and Clinical Research, National Cancer Center Research 
      Institute, Tokyo, Japan; Department of Oral and Maxillofacial Surgery, Tokyo 
      Dental College, Chiba, Japan.
FAU - Mori, T
AU  - Mori T
AD  - Department of Pathology and Clinical Laboratories, National Cancer Center 
      Hospital, Tokyo, Japan.
FAU - Yoshimoto, S
AU  - Yoshimoto S
AD  - Department of Head and Neck Oncology, National Cancer Center Hospital, Tokyo, 
      Japan.
FAU - Watabe, Y
AU  - Watabe Y
AD  - Department of Oral and Maxillofacial Surgery, Tokyo Dental College, Chiba, Japan.
FAU - Miura, N
AU  - Miura N
AD  - Division of Chemotherapy and Clinical Research, National Cancer Center Research 
      Institute, Tokyo, Japan.
FAU - Shoji, H
AU  - Shoji H
AD  - Division of Chemotherapy and Clinical Research, National Cancer Center Research 
      Institute, Tokyo, Japan.
FAU - Onidani, K
AU  - Onidani K
AD  - Division of Chemotherapy and Clinical Research, National Cancer Center Research 
      Institute, Tokyo, Japan.
FAU - Shibahara, T
AU  - Shibahara T
AD  - Department of Oral and Maxillofacial Surgery, Tokyo Dental College, Chiba, Japan.
FAU - Honda, K
AU  - Honda K
AD  - Division of Chemotherapy and Clinical Research, National Cancer Center Research 
      Institute, Tokyo, Japan; Japan Agency for Medical Research and Development (AMED) 
      CREST, Tokyo, Japan. Electronic address: khonda@ncc.go.jp.
LA  - eng
PT  - Journal Article
DEP - 20170425
PL  - Denmark
TA  - Int J Oral Maxillofac Surg
JT  - International journal of oral and maxillofacial surgery
JID - 8605826
RN  - 0 (ACTN4 protein, human)
RN  - 0 (Biomarkers, Tumor)
RN  - 11003-00-2 (Actinin)
SB  - IM
MH  - Actinin/*genetics
MH  - Aged
MH  - Biomarkers, Tumor/analysis
MH  - Female
MH  - *Gene Amplification
MH  - Glossectomy
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Lymphatic Metastasis/*genetics
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Survival Rate
MH  - Tongue Neoplasms/*genetics/mortality/pathology/surgery
OTO - NOTNLM
OT  - ACTN4
OT  - early stage oral tongue cancer
OT  - gene amplification
OT  - prognostic biomarker
EDAT- 2017/04/08 06:00
MHDA- 2018/05/16 06:00
CRDT- 2017/04/08 06:00
PHST- 2016/07/26 00:00 [received]
PHST- 2017/01/26 00:00 [revised]
PHST- 2017/03/02 00:00 [accepted]
PHST- 2017/04/08 06:00 [pubmed]
PHST- 2018/05/16 06:00 [medline]
PHST- 2017/04/08 06:00 [entrez]
AID - S0901-5027(17)31345-0 [pii]
AID - 10.1016/j.ijom.2017.03.001 [doi]
PST - ppublish
SO  - Int J Oral Maxillofac Surg. 2017 Aug;46(8):968-976. doi: 
      10.1016/j.ijom.2017.03.001. Epub 2017 Apr 25.